Hiroshi Ishiai
Comptroller/Controller/Auditor bei Modulus Discovery, Inc.
Ursprung des Netzwerks ersten Grades von Hiroshi Ishiai
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Modulus Discovery, Inc.
 Modulus Discovery, Inc. BiotechnologyHealth Technology Modulus Discovery, Inc. preclinical stage drug Discovery Company. It is focused on rapid design and generation of small molecule clinical candidates for disease targets through the use of its cutting-edge computational drug discovery expertise and unique biology insights. The company was founded by Shun Roy Kimura And Kazuki Ohno and is headquartered in Minato-ku, Japan.
3
| Holding Company | Biotechnology | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Hiroshi Ishiai
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Fast Track Initiative, Inc.
 Fast Track Initiative, Inc. Investment ManagersFinance Fast Track Initiative, Inc. (FTI) is a Venture Capital firm, a subsidiary of Life Science Management, Inc. founded in 2004 by Koichi Ashida and Hiromichi Kimura. Fast Track Initiative, Inc. is headquartered in Tokyo with additional office in the Unites States. | Investment Managers | Private Equity Investor | |
AccuRna, Inc.
 AccuRna, Inc. BiotechnologyHealth Technology AccuRna, Inc. researches and develops nucleic acid-based drugs using drug delivery system technologies. The company was founded on December 18, 2015 and is headquartered in Tokyo, Japan. | Biotechnology | Director/Board Member | |
Braizon Therapeutics, Inc.
 Braizon Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Braizon Therapeutics, Inc. is a Japanese company that engages in researching and developing drugs. The company was founded in 2015 by Mariko Tosu. The CEO is Bunichi Wanibuchi. | Miscellaneous Commercial Services | Director/Board Member | |
PuREC KK
 PuREC KK BiotechnologyHealth Technology PuREC KK is a company based in Japan that aims to revolutionize the future of regenerative medicine by developing a high-purity mesenchymal stem cell culture technology called REC (Rapidly Expanding Cell). REC has approximately 1000 times more pharmacological efficacy in terms of proliferation and differentiation compared to normal mesenchymal stem cells, making it effective in treating a wide range of diseases. The Japanese company was founded in 2016 by Shotai Kobayashi. | Biotechnology | Director/Board Member | |
| MODALIS THERAPEUTICS CORPORATION | Biotechnology | Director/Board Member |
Statistik
International
| Japan | 6 |
Sektoral
| Health Technology | 4 |
| Finance | 2 |
| Commercial Services | 2 |
Operativ
| Director/Board Member | 7 |
| Founder | 2 |
| Private Equity Investor | 1 |
| Chief Executive Officer | 1 |
| Chief Operating Officer | 1 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Tomohiro Anzai | 6 |
| Shun Roy Kimura | 1 |
| Kazuki Ohno | 1 |
- Börse
- Insiders
- Hiroshi Ishiai
- Unternehmensverbindungen
